The role of neurotrophins and insulin on tau pathology in Alzheimer's disease

Reviews in the Neurosciences

Volumn 17, Issue 6, 2006, Pages 635-642

  Elliott, Evan ^a   Ginzburg, Irith ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Alzheimer's disease; BDNF; Insulin; Neurotrophins; Phosphorylation; Tau

Indexed keywords

INSULIN; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NEUROTROPHIN; TAU PROTEIN;

ALZHEIMER DISEASE; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISEASE COURSE; HUMAN; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 33846432364     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/REVNEURO.2006.17.6.635     Document Type: Review

References (50)

1. Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA 1994; 91: 5562-5566.
2. Babu JR, Geetha T, Wooten MW. Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem 2005; 94: 192-203.
3. Bagnoli S, Nacmias B, Tedde A, Guarnieri BM, Cellini E, Petruzzi C, Bartoli A, Ortenzi L, Sorbi S. Brain-derived neurotrophic factor genetic variants are not susceptibility factors to Alzheimer's disease in Italy. Ann Neurol 2004; 55: 447-448.
4. Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K, Seitelberger F, Grundke-Iqbal I, Iqbal K, Wisniewski HM. Tau and ubiquitin immunoreactivity at different stages of formation of Alzheimer neurofibrillary tangles. Prog Clin Biol Res 1989; 317: 837-848.
5. Bhat RV, Budd Haeberlein SL, Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 2004; 89: 1313-1317.
6. Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 1993; 11: 153-163.
7. Bodner SM, Berrettini W, van Deerlin V, Bennett DA, Wilson RS, Trojanowski JQ, Arnold SE. Genetic variation in the brain derived neurotrophic factor gene in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2005; 134: 1-5.
8. Boissiere F, Faucheux B, Ruberg M, Agid Y, Hirsch EC. Decreased TrkA gene expression in cholinergic neurons of the striatum and basal forebrain of patients with Alzheimer's disease. Exp Neurol 1997; 145: 245-252.
9. Capsoni S, Ugolini G, Comparini A, Ruberti F, Berardi N, Cattaneo A. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci USA 2000; 97: 6826-6831.
10. Cheng CM, Tseng V, Wang J, Wang D, Matyakhina L, Bondy CA. Tau is hyperphosphorylated in the insulin-like growth factor-I null brain. Endocrinology 2005; 146: 5086-5091.
11. Crutcher KA, Scott SA, Liang S, Everson WV, Weingartner J. Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer's disease. J Neurosci 1993; 13: 2540-2550.
12. Elliott E, Atlas R, Lange A, Ginzburg I. Brain-derived neurotrophic factor induces a rapid dephosphorylation of tau protein through a PI-3 kinase signalling mechanism. Eur J Neurosci 2005; 22: 1081-1089.
13. Path T, Eidenmuller J, Brandt R. Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease. J Neurosci 2002; 22: 9733-9741.
14. Fisher A, Heldman E, Gurwitz D, Haring R, Karton Y, Meshulam H, Pittel Z, Marciano D, Brandeis R, Sadot E, Barg Y, Pinkas-Kramarski R, Vogel Z, Ginzburg I, Treves TA, Verchovsky R, Klimowsky S, Korczyn AD. M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update. Ann NY Acad Sci 1996; 777: 189-196.
15. Frey BN, Andreazza AC, Cereser KM, Martins MR, Valvassori SS, Reus GZ, Quevedo J, Kapczinski F. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci 2006; 79: 281-286.
16. Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheimer A, Turk A, Hoyer S, Zochling R, Boissl KW, Jellinger K, Riederer P. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 1998; 105: 423-438.
17. Garzon D, Yu G, Fahnestock M. A new brain-derived neurotrophic factor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer's disease parietal cortex. J Neurochem 2002; 82: 1058-1064.
18. Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta 2005; 1739: 240-250.
19. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986; 83: 4913-4917.
20. Higuchi M, Lee VM, Trojanowski JQ. Tau and axonopathy in neurodegenerative disorders. Neuromolecular Med 2002; 2: 131-150.
21. Hong M, Lee VM. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 1997; 272: 19547-19553.
22. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 2004; 490: 115-125.
23. Johnson GV, Jenkins SM. Tau protein in normal and Alzheimer's disease brain. J Alzheimers Dis 1999; 1: 307-328.
24. Jones KR, Farinas I, Backus C, Reichardt LF. Targeted disruption of the BDNF gene perturbs brain and sensory neuron development but not motor neuron development. Cell 1994; 76: 989-999.
25. Kosik KS, Shimura H. Phosphorylated tau and the neurodegenerative foldopathies. Biochim Biophys Acta 2005; 1739: 298-310.
26. Kunugi H, Ueki A, Otsuka M, Isse K, Hirasawa H, Kato N, Nabika T, Kobayashi S, Nanko S. A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer's disease. Mol Psychiatry 2001; 6: 83-86.
27. Ledesma MD, Bonay P, Avila J. Tau protein from Alzheimer's disease patients is glycated at its tubulin-binding domain. J Neurochem 1995; 65: 1658-1664.
28. Ledesma MD, Bonay P, Colaco C, Avila J. Analysis of microtubule- associated protein tau glycation in paired helical filaments. J Biol Chem 1994; 269: 21614-21619.
29. Lesort M, Johnson GV. Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons. Neuroscience 2000; 99: 305-316.
30. Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkow E, Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 2003; 24: 1079-1085.
31. Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, Mears A, Drummond JA, Berg S, MacKay D, Asuni AA, Bhat R, Lovestone S. GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry 2004; 9: 522-530.
32. Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 2001; 63: 71-124.
33. Nuydens R, Dispersyn G, de Jong M, van den Kieboom G, Borgers M, Geerts H. Aberrant tau phosphorylation and neurite retraction during NGF deprivation in PC 12 cells. Biochem Biophys Res Commun 1997; 240: 687-691.
34. Olin D, MacMurray J, Comings DE. Risk of late-onset Alzheimer's disease associated with BDNF C270T polymorphism. Neurosci Lett 2005; 381: 275-278.
35. Patapoutian A, Reiehardt LF. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol 2001; 11: 272-280.
36. Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem 2005; 93: 1412-1421.
37. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 1991; 7: 695-702.
38. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 2002; 99: 6364-6369.
39. Riemenschneider M, Schwarz S, Wagenpfeil S, Diehl J, Muller U, Forstl H, Kurz A. A polymorphism of the brain-derived neurotrophic factor (BDNF) is associated with Alzheimer's disease in patients lacking the apolipoprotein E ε4 allele. Mol Psychiatry 2002; 7: 782-785.
40. Sadot F. Heicklen-Klein A, Barg J, Lazarovici P, Ginzburg I. Identification of a tau promoter region mediating tissue-specific-regulated expression in PC 12 cells. J Mol Biol 1996; 256: 805-812.
41. Schechter R, Beju D, Miller KE. The effect of insulin deficiency on tau and neurofilament in the insulin knockout mouse. Biochem Biophys Res Commun 2005; 334: 979-986.
42. Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, Farhang-Fallah J, Dikkes P, Warot XM, Rio C, Corfas G, White MF. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 2003; 23: 7084-7092.
43. Scott SA, Mufson EJ, Weingartner JA, Skau KA, Crutcher KA. Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci 1995; 15: 6213-6221.
44. Shelton SB, Johnson GV. Tau and HMW tau phosphorylation and compartmentalization in apoptotic neuronal PC12 cells. J Neurosci Res 2001; 66: 203-213.
45. Shimura H, Schwartz D, Gygi SP, Kosik KS. CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem 2004; 279: 4869-4876.
46. Siegel GJ, Chauhan NB. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Brain Res Rev 2000; 33: 199-227.
47. Tong L, Balazs R, Thornton PL, Cotman CW. Beta-amyloid peptide at sublethal concentrations down-regulates brain-derived neurotrophic factor functions in cultured cortical neurons. J Neurosci 2004; 24: 6799-6809.
48. Tsai SJ, Hong CJ, Liu HC, Liu TY, Hsu LE, Lin CH. Association analysis of brain-derived neurotrophic factor Val66Met polymorphisms with Alzheimer's disease and age of onset Neuropsychobiology 2004; 49: 10-12.
49. Tuszynski MH, Thai L, Pay M, Salmon DP, U HS, Bakay R, Patel P, Blesch A, Vahlsing HL, Ho G, Tong G, Potkin SG, Fallon J, Hansen L, Mufson EJ, Kordower JH, Gall C, Conner J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11: 551-555.
50. Ventriglia M, Bocchio Chiavetto L, Benussi L, Binetti G, Zanetti O, Riva MA, Gennarelli M. Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer's disease. Mol Psychiatry 2002; 7: 136-137.